Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/21/21 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
4 | |
| 05/20/21 | 8-K | Current report filing |
|
   |
7 |
| 05/19/21 | UPLOAD | SEC-generated letter |
|
2 | |
| 05/17/21 | 8-K | Current report filing |
|
|
6 |
| 05/07/21 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
5 | |
| 04/29/21 | 8-K | Current report filing |
|
|
47 |
| 04/21/21 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 04/21/21 | 8-K | Current report filing |
|
|
8 |
| 04/16/21 | UPLOAD | SEC-generated letter |
|
2 | |
| 04/14/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
80 |
